MCL1 and cancer: Strikingly, in three out of 25 tested cancer types, survival of the high scoring group (high activation of FGF signalling and high expression of BCL-2 or MCL-1) was significantly decreased when compared to the low scoring group (Fig. 6f, Supplementary Fig. 6a, b).